ARVN (Arvinas) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARVN Arvinas Inc ARVN
66 GF Score
Price $8.02
GF Value $12.36
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arvinas Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

ARVN
66GF Score
Arvinas Inc ARVN
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arvinas (ARVN) Overvalued in 2026?

Based on GuruFocus' analysis, Arvinas stock appears to be undervalued. The current stock price of $8.02 is trading 35.1% below its estimated GF Value™ of $12.36. GuruFocus considers Arvinas to be Possible Value Trap.

Key valuation signals for ARVN:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $12.36 vs. price of $8.02 (35.1% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arvinas Business Description

Address 395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
66GF Score

Get the complete analysis for ARVN

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.02
Price
$12.36
GF Value